ProMIS Neurosciences Inc. is trading at $10.56 (up 5.1%), extending gains following a presentation by its CEO at the H.C. Wainwright Neuro Perspectives Expert Summit.

  • During the June 15, 2026, presentation, leadership highlighted the company's proprietary EpiSelectâ„¢ platform and its lead Alzheimer’s disease candidate, PMN310.
  • The stock is benefiting from a recent Zacks upgrade, which has improved analyst sentiment and increased visibility for the company's clinical pipeline.
  • Today's move is a continuation of the bullish momentum that began during after-hours trading on June 15 as investors react to the summit highlights.